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Insights into the Complexity and Functionality of Hepatitis C Virus
NS5A Phosphorylation
Douglas Ross-Thriepland, Mark Harris
School of Molecular and Cellular Biology, Faculty of Biological Sciences and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, United Kingdom
The hepatitis C virus nonstructural NS5A protein has roles in genome replication, virus assembly, and modulation of host path-
ways. NS5A is a phosphoprotein, and it has been proposed that differential phosphorylation could regulate the various roles of
the protein. By SDS-PAGE, two forms of NS5A with distinct apparent molecular weights can be observed, referred to as basally
phosphorylated and hyperphosphorylated species. However, the sites of phosphorylation on these two species have not been
unequivocally identified, hampering our understanding of the function and regulation of NS5A. To address this, we purified
tagged NS5A from cells harboring a replicating subgenomic replicon and analyzed the purified protein by mass spectrometry.
We identified six peptide fragments containing 12 phosphorylated residues and were able to assign four of these to serines 146,
222, and 225 and threonine 348. A serine-rich peptide fragment spanning residues 221 to 240 was highly phosphorylated. Using
mutagenesis, we identified roles for a subset of these phosphoacceptors in virus genome replication. We further showed that
phosphorylation at S146 regulates hyperphosphorylation, and by generating a phospho-specific antibody targeted to pS222, we
identified that S222 phosphorylation predominates in the hyperphosphorylated species. Last, by introducing phosphomimetic
mutations across residues 221 to 240, we demonstrated changes in the mobility of the basally phosphorylated species suggestive
of a sequential phosphorylation cascade within this serine-rich cluster. We propose that this regulation could drive a conforma-
tional switch between the dimeric structures of NS5A and could also explain the different functions of the protein in the virus
life cycle.
Hepatitis C virus (HCV) has infected an estimated 3% of theworld’s population (170 million individuals); in 85% of
cases, the virus establishes a chronic infection leading to liver cir-
rhosis and hepatocellular carcinoma (1). HCV has a 9.6-kb posi-
tive-sense, single-stranded RNA genome coding for an 3,000-
amino-acid polyprotein that is cleaved co- and posttranslationally
by both host and viral proteases to produce 10 mature viral pro-
teins. At the N terminus of the polyprotein are the structural pro-
teins, Core, E1, and E2, which make up the virus particle. These
are followed by the viroporin p7, which has roles in virus assembly
and release (2), and the nonstructural protein 2 (NS2), which
contains an autoprotease activity that cleaves it fromNS3 but also
has a poorly defined role in virion morphogenesis (3, 4). The
remaining NS proteins, NS3, NS4A, NS4B, NS5A, and NS5B, are
responsible for the replication of the viral genome, but more re-
cently, with the advent of a full-length clone of a genotype 2a
isolate (JFH-1) able to undergo the complete virus life cycle in cell
culture, these proteins have been shown to play roles in virion
assembly and release.
In this regard, the NS5A protein has clearly been shown to play
key roles in both genome replication and virion assembly/release,
but as yet the precise nature of these two functions of the protein
and how they are regulated remain to be elucidated. NS5A is com-
prised of an N-terminal amphipathic helix that anchors the pro-
tein to cytoplasmicmembranes, followed by three domains linked
by two low-complexity sequences (LCS) (see Fig. 1A) that are
either serine or proline rich (termed LCS I and II, respectively).
Domain I is a highly structured, zinc binding domain whose
three-dimensional structure shows two different dimeric confor-
mations (5, 6). Domains II and III have been shown to be natively
unstructured, but nuclear magnetic resonance (NMR) and circu-
lar dichroism (CD) show that both these domains have elements
of secondary structure throughout (7–9). NS5A is a phosphopro-
tein, and it is widely accepted that NS5A exists as two forms with
slightly different mobilities on an SDS-PAGE gel—these have
been termed basally phosphorylated (apparent molecular mass of
56 kDa) and hyperphosphorylated (58-kDa) species. The identi-
ties of the kinases that phosphorylate NS5A and the sites of phos-
phorylation remain to be unambiguously determined. A range of
kinases have been reported to phosphorylate NS5A either in vitro
or in vivo; these include casein kinases I and II (CKI and CKII)
(10–12), polo-like kinase 1 (Plk1) (13), glycogen synthase kinase 3
(GSK3), andmitogen-activated protein kinases (MAPK) (14; for a
review, see reference 15). A number of early studies provided ev-
idence for the identities of the phosphorylation sites on NS5A; for
example, it was shown (16) that mutation of serines at residue
2197, 2201, or 2204 (polyprotein numbering, corresponding to
225, 229, and 232 in NS5A) resulted in a loss of the hyperphos-
phorylated species in Cos7 cells transfected with a plasmid ex-
pressing NS2-NS5B. These residues are located within LCS I and
are absolutely conserved throughout all isolates of HCV. Two
studies used mass spectrometry analysis of either glutathione S-
transferase (GST)-tagged NS5A (GST-NS5A) expressed using a
vaccinia-T7 system in BHK21 cells (17) or purified baculovirus-
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expressed NS5A phosphorylated in vitro (18) to identify putative
phosphorylation sites. Both of these studies used a genotype 1b
NS5A isolate and identified single phosphorylation sites at S2321
(349 in NS5A) or S2194 (222 in NS5A), respectively. It is impor-
tant to note that these studies involved expression of NS5A in the
absence of other viral proteins. Given the fact that various studies
have shown that hyperphosphorylation is dependent on other
nonstructural proteins (19–21), clearly these data should be inter-
preted with caution.
Since these early reports, the phenotypes of mutations in these
putative phosphorylation sites have been investigated in the con-
text of both subgenomic replicons and full-length JFH-1 virus.
These data are difficult to interpret, but a consensus has emerged
that in the context of genotype 1b subgenomic replicons, hyper-
phosphorylation negatively regulates RNA replication (22, 23).
However, although the same mutations also abolish hyperphos-
phorylation in genotype 2a, the negative regulation of RNA repli-
cation was not observed (24).
The Tellinghuisen group has shown, using mutagenesis and
pharmacological inhibitors, that a serine at residue 457 is a poten-
tial CKII phosphorylation site that may play a role in virus assem-
bly (12), although they did not provide biochemical (mass spec-
trometric) evidence for this. More recently, they demonstrated by
mass spectrometry that S222 was a major phosphorylation site in
a JFH-1 subgenomic replicon and that mutation of this residue to
aspartic acid (as a phosphomimetic) had a modest inhibitory ef-
fect on RNA replication (25). A phosphoablatant mutation at
S222 (to alanine) also had a modest inhibitory effect on hyper-
phosphorylation.
Taken together, these data point to the absolutely conserved
serine cluster in LCS I as the major site for hyperphosphorylation
in NS5A; however, given that NS5A is both serine and threonine
rich (JFH-1 NS5A contains 48 serines and 37 threonines: nearly
20% of the protein), there is a great propensity for additional
phosphorylation events elsewhere on the protein. Phosphoryla-
tion has been proposed to act as a molecular switch regulating the
different functions of NS5A (22), although there is as yet no direct
experimental evidence to support this hypothesis.
A comprehensive understanding of the phosphorylation and
function of NS5A will require the identification of physiologically
relevant phosphorylation sites, i.e., those present on NS5A in cells
actively replicating viral RNA. To address this issue, we have
therefore undertaken a mass spectrometric analysis of JFH-1
NS5A purified on a large scale from Huh7 cells harboring an
NS3-5B subgenomic replicon. As expected, this analysis revealed
multiple phosphorylation sites, and we have complemented this
analysis with mutagenesis to determine the phenotypes of these
phosphorylation events in the context of both subgenomic repli-
cons and virus. Our data reveal a complex pattern of phosphory-
lation within LCS I and provide evidence for a sequential cascade
of phosphorylation across this region and for regulation by a distal
phosphorylation event within domain I.
MATERIALS AND METHODS
DNA constructs. DNA constructs of either the full-length pJFH-1 virus
(26), luciferase reporter subgenomic replicon (SGR-luc-JFH-1) (27), or
neomycin reporter SGR with NS5A containing a One-Strep tag (1ST)
(pSGR-5A1ST) (28) were used throughout. Previously, unique restriction
sites flanking NS5A, BamHI and AfeI, were introduced into both full-
length virus and SGR-luc-JFH-1 constructs; these constructs were de-
noted as mJFH-1 and mSGR-luc-JFH-1, respectively, and shown to have
no effect on virus genome replication or assembly and release (29). Mu-
tagenesis of NS5A was performed on a LITMUS28i (NEB) subclone con-
taining an NsiI/HindIII fragment of the mJFH-1 cDNA by QuikChange
site-directed mutagenesis (Stratagene) and then cloned into either
mSGR-luc-JFH-1 or mJFH-1 via the flanking BamHI/AfeI sites. All mu-
tations were verified by sequencing; plasmid and primer sequences are
available on request.
Cell culture. Huh7 cells were cultured in Dulbecco’s modified Eagle’s
Medium (DMEM) (Sigma) supplemented with 10% fetal bovine serum
(FBS), 100 IU penicillin/ml, 100 g streptomycin/ml, and 1% nonessen-
tial amino acids in a humidified incubator at 37°C, 5% CO2. For virus
propagation, medium was supplemented with 25 mMHEPES. Replicon-
harboring cells containing a neomycin resistance genewere selected for 20
days postelectroporation at 1mg/ml G418 (Sigma) before passaging at 1:5
every 3 days under 0.5-mg/ml G418 selection.
Purification of NS5A. A stable Huh7 cell line harboring the SGR-
5A1ST subgenomic replicon was passaged as described above. At each
passage, excess cells were washed twice in phosphate-buffered saline
(PBS), pelleting at 500  g, 5 min at room temperature, before lysis in
Glasgow lysis buffer (30) (GLB) [1% Triton X-100, 120 mMKCl, 30 mM
NaCl, 5 mM MgCl2, 10% glycerol, and 10 mM piperazine-N,N=-bis(2-
ethanesulfonic acid) (PIPES)-NaOH, pH 7.2] containing protease and
phosphatase inhibitors, 2 ml per 175-cm2 flask. Lysates were clarified by
centrifugation at 4,000  g, 5 min at 4°C, and filtered through a 0.45-m
cellulose filter before batch affinity purification of NS5A-1ST on Strep-
Tactin Sepharose columns (IBA), with a 5-ml column volume, following
the manufacturer’s instructions. Bound protein was washed with 1 col-
umn volume of wash buffer supplemented with low salt (0.5 M NaCl) or
high salt (1 M NaCl and 1% Triton X-100) for three and four washes,
respectively, before two standard washes and competitive elution with 2.5
mM desthiobiotin at 0.5 column volume. Peak elution fractions, 3 and 4,
were identified byWestern blotting and concentrated, first by centrifuga-
tion filtration (10,000 [10K]-molecular-weight cutoff) followed bymeth-
anol-chloroform precipitation. The final precipitate was resuspended in
20 l of 1 SDS-LB and separated further on a 12% Tris-glycine SDS-
PAGEgel. After stainingwithCoomassie R250, the band corresponding to
NS5A was excised for mass spectrometry analysis.
Mass spectrometry analysis. An excised gel slice was sectioned in two
and subjected to in-gel digestion with either GluC or trypsin, following
standard protocols. Peptide fragments eluted from gel slices and phos-
phopeptides were enriched by titanium dioxide enrichment. Samples
were analyzed by liquid chromatography-electrospray ionization-tandem
mass spectrometry (LC-ESI-MS/MS) or LC–matrix-assisted laser desorp-
tion ionization–MS/MS (LC-MALDI-MS/MS) as denoted, and resulting
MS andMS/MS spectra were interrogated by using the software program
Mascot (Matrix Science), with identified phosphopeptides confirmed
manually.
In vitro transcription. DNA constructs were linearized by XbaI,
mung bean nuclease treated, and phenol-chloroform extracted. Linear-
ized DNA was then used as the template in a RiboMAX reaction (Pro-
mega). RNA transcripts were purified by phenol-chloroform extraction,
quantified by absorbance at 260 nm, and analyzed by agarose gel electro-
phoresis to confirm integrity and quantification.
Luciferase-based replication assay. Huh7 cells were washed twice in
diethylpyrocarbonate (DEPC)-treated PBS before electroporating 4 
106 cells in DEPC-PBS with 2 g of RNA at 950 F and 270 V. Cells were
resuspended in complete medium before being seeded into both 96-well
plates (n  6) at 3  104 cells/well and 6-well plates (n  2) at 3  105
cells/well, both plates incubated under cell culture conditions. At 4 and 72
h postelectroporation (hpe), cells were harvested by lysis with either 30l
or 200 l passive lysis buffer (PLB) (Promega), 96- and 6-well, respec-
tively. Luciferase activity was determined from 96-well samples on a BMG
plate.
Ross-Thriepland and Harris
1422 jvi.asm.org Journal of Virology
 o
n
 January 15, 2014 by UNIVERSITY O
F LEEDS
http://jvi.asm.org/
D
ow
nloaded from
 
Virus replication and release assay. Huh7 cells were washed twice in
DEPC-PBS before electroporating 2 106 cells inDEPC-PBSwith 1g of
RNA at 960 F and 270 V. Cells were resuspended in complete medium
and seeded at 106 cells/well into 6-well plates. At 72 hpe, cells were split at
1:5 before incubating for a further 72 h. At 144 hpe, cells were harvested in
400l TRIzol reagent for real-time quantitative PCR (qRT-PCR) analysis,
while supernatants were removed and clarified at 2,800  g for 5 min at
room temperature before storing at 80°C.
Virus titer determination by focus-forming assay. Titers of clarified
virus supernatants were determined onHuh7 cells as follows. In a 96-well
format, clarified virus supernatants were serially diluted 5-fold in com-
plete DMEM medium plus HEPES before the addition of 100 l diluted
virus to Huh7 cells seeded 24 h previously into 96-well plates at 8  103
cells/well, with a final volume of 200 l. Cells were incubated under nor-
mal cell culture conditions for 72 h before fixation, staining, and focus
counting as described previously (31).
RNA extraction and qRT-PCR. To quantify the number of HCV ge-
nomes, total cell RNA was extracted by TRIzol, following the manufac-
turer’s instructions (Invitrogen). Total extracted cellular RNA, 100 ng,
was analyzed by qRT-PCR using a one-step qRT-PCR TaqMan-based kit
as directed (Eurogentec), with primers and probe designed against the 5=
untranslated region (UTR) as described previously (32).
SDS-PAGE/Western blotting. Cells were washed twice with PBS,
lysed by resuspension inGLB containing protease and phosphatase inhib-
itors, and incubated on ice for 15 min. Insoluble material was pelleted by
centrifugation at 500  g for 5 min at 4°C. Following separation by SDS-
PAGE, proteins were transferred to a polyvinylidene difluoride (PVDF)
membrane and blocked in 50%Odyssey blocking buffer (Li-Cor) in PBS.
The membrane was incubated with primary antibody in 50% Odyssey
blocking buffer and then incubated with fluorescently labeled anti-goat
(800 nm) or anti-mouse (700 nm) before imaging on a Li-Cor Odyssey Sa
infrared imaging system. Primary antibodies used were as follows: NS5A
(9E10), 1:5,000 (a kind gift from Tim Tellinghuisen); NS5A (sheep),
1:10,000 (30); Core (sheep), 1:5,000 (in house); glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), 1:30,000 (Sigma).
Quantification of basal/hyperphosphorylation. Quantification of
fluorescently labeled Western blots was carried out using Image Studio
v3.1 software (Li-Cor) using a background subtraction method.
Validation of phospho-specific pS222 antibody. For Western blot-
ting, PVDF membranes were blocked in 5% (wt/vol) bovine serum albu-
min (BSA)-Tris-buffered saline (TBS) for 1 h at room temperature before
incubation with primary antibody at 1 g/l with 10 g/ml nonphos-
phorylated 13-mer peptide in 50% Odyssey blocking buffer in TBS. Note
that antibody/nonphosphorylated peptide was preincubated for 1 h at
room temperature.
Statistics. Data sets analyzed using Student’s t test assuming a two-
tailed, unequal variance to determine the statistical difference from results
for the wild type (WT) (n  3 or greater throughout; , P  0.05; , P 
0.01).
RESULTS
Identification of NS5A phosphorylation sites by mass spec-
trometry. NS5A is known to be highly phosphorylated; however,
with the exception of a recent study (25), the site(s) of phosphor-
ylation on NS5A expressed in a physiologically relevant context,
i.e., in human hepatocytes either infected with HCV or harboring
subgenomic replicons, has not been definitively determined. To
address this gap in our understanding, we took advantage of the
fact that domain III of NS5A is able to tolerate in-frame insertions
with no effect on the functions of the protein in virus RNA repli-
cation or assembly. Specifically, we utilized a subgenomic replicon
in which NS5A was tagged with the One-Strep affinity tag (1ST);
the insertion of this short tag had been previously shown not to
affect RNA replication (28) and provided a highly efficient and
selective purification strategy. NS5A-1ST was affinity purified us-
ing Strep tag beads from cytoplasmic lysates of approximately 5
109 cells prior to separation by SDS-PAGE.After staining of the gel
with Coomassie brilliant blue R250, the band corresponding to
NS5A was excised and subjected to either trypsin or GluC cleav-
age, TiO2 enrichment of phosphorylated peptides, andmass spec-
trometry analysis by MS-MS utilizing both MALDI and ESI ap-
proaches to identify phosphorylated species.
This analysis allowed the unambiguous assignment of four
phosphorylation sites on different phosphopeptides (Fig. 1A and
B and Table 1; see also Fig. S1 to S4 in the supplemental material):
first, a peptide located within domain I in which serine 146 was
phosphorylated; second, two peptides located within the serine-
rich LCS I between domains I and II (one of these peptides con-
tained a single phosphoserine at residue 222, and the other con-
tained two phosphoserines at residues 222 and 225); the fourth
peptide was located in the proline-rich LCS II between domains II
and III and contained a phosphothreonine at residue 348.
A number of other phosphopeptides mapping to the LCS I
were identified by MS/MS to be extensively phosphorylated, con-
taining between 3 and 7 phosphorylated residues (Fig. 1C). The
exact arrangement of phosphorylations in these peptide species
could not be identified. In the case of the tri-, tetra-, and penta-
phosphorylated species, MS/MS data showed that S229, S230,
S232, and S235 were phosphorylated residues but that these phos-
phorylation events were occurring in an arrangement of different,
unassignable isomers. In the case of the hexa- and heptaphos-
phorylated species, the ion suppression effects caused by multiple
phosphorylations resulted in insufficient ion abundance for
MS/MS data to be collected; as such, no assignment could be car-
ried out. For similar reasons, the presence of an octaphosphory-
lated species of the peptide fragment spanning 221 to 240, cannot
be excluded. Our data point to a complex pattern of phosphory-
lation in this region of NS5A, and this concept is explored further
later in the article.
Three other phosphopeptides were also identified as contain-
ing a single phosphorylated residue—these corresponded to pep-
tides 241 to 273, 375 to 395, and 396 to 409 (Table 1). TheMS/MS
data were not sufficient to allow the unambiguous assignment of
the phosphorylated reside in each phosphopeptide, but was able
to identify a subset of serines/threonines at which phosphoryla-
tion was occurring. Due to the uncertainties resulting from the
analysis of these phosphopeptides, this study instead focused on
those phosphoacceptors for which evidence was more conclusive.
Role of NS5A phosphorylation in HCV life cycle. To investi-
gate the role of the four unambiguously identified phosphoryla-
tion sites in the virus life cycle, each residue was mutated to either
alanine to block phosphorylation (phosphoablatant) or aspartic
acid to introduce a negative charge, thereby acting as a phospho-
mimetic. These mutations were introduced into both a luciferase-
based subgenomic replicon (SGR-luc-JFH-1) or a full-length
JFH-1 virus construct, allowing us to assess the role of phosphor-
ylation at different stages of the virus life cycle. In addition to the
four single site mutations, the two serines at 222 and 225 were
mutated simultaneously. Figure 2A shows the results of this mu-
tagenesis in the context of the subgenomic replicon. Neither the
phosphoablatant nor phosphomimetic mutations at serines 146
and 222 (S146A/D and S222A/D) or threonine 348 (T348A/D)
had any significant effect on RNA replication. All of the resulting
mutated subgenomic replicons were able to replicate with equal
Complex Phosphorylation of NS5A
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efficiency (100-fold increase in luciferase expression over 72 h
postelectroporation [hpe]). In contrast, the S225A phosphoabla-
tant mutation resulted in a 10-fold reduction in replication,
whereas an S225D mutant exhibited wild-type levels of replica-
tion, suggesting that phosphorylation of this residue is important
for HCV genome replication. Consistent with this, the double
alanine substitution (S222/225A) almost completely abolished the
replicative ability of the subgenomic replicon, with levels of lucif-
erase activity at 72 hpe only slightly higher than those of the GND
negative control (which contains an inactivating mutation in the
NS5B polymerase). The corresponding double aspartic acid sub-
stitution (S222/225D) had wild-type activity. We conclude that
S222 phosphorylation makes a modest contribution to genome
replicationwhich is apparent only in the context of a further phos-
phorylation event at S225.
By Western blotting, wild-type NS5A appears as a doublet of
what have been referred to as basally and hyperphosphorylated
species. Of note, although these two species are commonly re-
ferred to as p56 and p58, in JFH-1, since there is an 18-amino-acid
insertion in domain III compared to genotype 1b (29), they mi-
grate with apparent molecular masses of 63 and 65kDa (see Fig.
S5A in the supplemental material). For clarity in this article, we
will refer to them as the basally and hyperphosphorylated species
of NS5A. To assess the potential effects of these mutations on
NS5A expression and the relative abundances of these two species,
lysates from cells electroporated with subgenomic replicon RNAs
were analyzed by Western blotting (Fig. 2B). In most cases, there
was no difference in the expression profile of NS5A compared to
that for the wild type. Where possible, the percentage of hyper-
phosphorylatedNS5Awas determined (Fig. 2C), although the low
levels of NS5A expression in the poorly replicating S225A and
S222/225A mutants did not allow quantitation. Surprisingly, the
S225D and S222/225D mutants exhibited a reduction in hyper-
phosphorylation, although these residues (along with S229 and
FIG 1 Mass spectrometric analysis of NS5A phosphorylation. (A) Schematic of NS5A structure showing amino acid residue numbers for JFH-1. AH, amphi-
pathic helix; LCS: low-complexity sequence. (B) Mass spectra of NS5A phosphopeptides after analysis by high-performance liquid chromatography (HPLC)-
MS/MS. The main monoisotopic peaks were selected for collision-induced dissociation (MS/MS) to allow the precise assignment of peptide and the phosphor-
ylated residues (see Fig. S1 to S4 in the supplementalmaterial). The locations of the four phosphopeptide species withinNS5A are indicated. (C) Themass spectra
of the NS5A phosphopeptides corresponding to the highly phosphorylated LCS I region, coeluted from the HPLC, resulting in simultaneous observation of all
species. Peaks identified asmono- to heptaphosphorylated species are indicated. The sequence of this peptide, together with the amino acid sequence numbering
for JFH-1 NS5A (bold) and the JFH-1 polypeptide, is presented below.Monoisotopic peaks for the tri, tetra, and penta species were selected forMS/MS; peptide
sequence could be assigned, but exactmapping of phosphorylated residues was hindered by the presence ofmultiple isomers of each species. Residues S229, S230,
S232, and S235, however, were observed as phosphorylated but in unassignable conformations. No MS/MS data could be acquired for the hexa- or heptaphos-
phorylated species.
Ross-Thriepland and Harris
1424 jvi.asm.org Journal of Virology
 o
n
 January 15, 2014 by UNIVERSITY O
F LEEDS
http://jvi.asm.org/
D
ow
nloaded from
 
S232) have previously been proposed as phosphoacceptor sites in
the hyperphosphorylated species of NS5A. This suggests that an
aspartate residue may mimic the charge but not the structural
effects of phosphorylation. Intriguingly, whereas the S146D mu-
tant exhibited a reduction in hyperphosphorylation, the S146A
mutant exhibited wild-type levels of hyperphosphorylated NS5A,
suggesting that while phosphorylated S146 is not a component of
hyperphosphorylated NS5A, it does negatively regulate hyper-
phosphorylation.
A similar set of data was obtainedwhen this series ofmutations
was evaluated in the context of the full-length JFH-1 infectious
clone (Fig. 3). The majority of the mutants showed wild-type lev-
els of both intracellular genome abundance measured by qRT-
PCR (Fig. 3A) and titers of released virus measured by focus-
forming assay (Fig. 3B). Again the S225A mutant exhibited an
approximately 10-fold reduction in both assays, and the S222/
225A mutant was almost completely deficient in both virus ge-
nome replication and assembly. Intriguingly, the S222D mutant
exhibited a modest but statistically significant reduction in re-
leased infectivity (Fig. 3B), but this was not seen at the level of
genome replication (Fig. 3A). It is therefore possible that S222
phosphorylation could regulate assembly and release of infectious
virus by inhibiting the (as yet undefined) role of NS5A in these
processes. The Western blot analysis (Fig. 3C) also paralleled that
observed for the subgenomic replicons. Although in this case a low
level of hyperphosphorylation could be seen in the context of the
S146Dmutant, this was clearly reduced compared to those of both
the wild type and the S146A mutant. We conclude that the phe-
notype of these mutants is entirely manifest at the level of virus
genome replication and there are no additional effects on virion
assembly or release.
Further analysis of phosphorylation within LCS I. In addi-
tion to themono- anddiphosphorylated peptidesmapping to LCS
I (S222 and S222/225), the mass spectrometric analysis revealed
evidence for the existence of phosphorylated species containing
between three and seven phosphorylation events (Table 1). In
order to investigate the potential function of these phosphoryla-
tion events, a further set of phosphoablatant and phosphomimetic
mutants was generated, and their phenotypes were evaluated in
the context of the SGR-luc-JFH-1 subgenomic replicon. As shown
TABLE 1 NS5A phosphopeptides identified by mass spectrometry
Peptide fragment observed by mass spectrometrya
No. of phosphorylation
events; location(s)b
[MH] Type of MS analysis used
Calculated Observed MALDI ESI MS/MS
KAPpTPPPR 1; T348 943.4761 943.4575 Yes No Yes
IPCQLPpSPE 1; S146 1120.4743 1120.4482 Yes Yes Yes
GpSPPSEASSSVSQLSAPSLR 1; S222 2023.9332 2023.9508 Yes Yes Yes
GpSPPpSEASSSVSQLSAPSLR 2; SS222/225 2103.8995 2103.8706 Yes Yes Yes
GSPPSEASSSVSQLSAPSLR 3; multiple isomers 2183.8659 2183.8477 Yes No Yes
GSPPSEASSSVSQLSAPSLR 4; multiple isomers 2263.8322 2263.811 Yes No Yes
GSPPSEASSSVSQLSAPSLR 5; multiple isomers 2343.7985 2343.7756 Yes No Yes
GSPPSEASSSVSQLSAPSLR 6; unassigned 2423.7648 2423.7419 Yes No No
GSPPSEASSSVSQLSAPSLR 7; unassigned 2503.7311 2503.7082 Yes No No
ATCTTHSNTYDVDMVDANLLMEGGVAQTEPESR 1; T242 or T244 or T245 or
S247 or T249
3724.5449 3724.5441 No Yes Yes
TFGQPPSSGDAGSSTGAGAAE 1; S387 or S388 1931.7655 1931.7629 No Yes Yes
SGGPTSPGEPAPSE 1; S396 or T400 or S401 1349.5257 1349.5414 Yes No Yes
a Bold and underlining in sequences indicate phosphorylated residues and putative phosphorylated residues respectively.
b JFH-1 NS5A protein numbering.
FIG 2 Mutagenic analysis of phosphorylation in the context of the HCV
subgenomic replicon. The indicated mutations were engineered into mSGR-
Luc-JFH-1 (29), in vitro transcribed RNA was electroporated into Huh7 cells,
and luciferase activity was measured at 4 and 72 hpe. A polymerase-inactive
mutant (GND)was included as a negative control. (A) Luciferase activity at 72
hpe is shown (n  3) normalized to activity at 4 h. , P  0.05, significance
difference from the wild type. (B)Western blot analysis of cell lysates at 72 hpe
probedwithNS5A (9E10) orGAPDHantibodies. Use of a 7.5%SDS-PAGE gel
allowed the separation of the basally (lower band) and hyperphosphorylated
(upper band) species of NS5A. (C) Quantification of the percentage of total
NS5A that is hyperphosphorylated from Western blot. Western blots were
imaged using a Li-Cor Odyssey Sa infrared imaging system, enabling highly
accurate quantification (n  3). , P  0.01, significant difference from the
wild type. n.d, no data due to low levels of expression. “SSAA” refers to the
S222/225A double mutant; “SSDD” refers to the corresponding S222/225D
mutant.
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in Fig. 4A, S228 and S230 did not appear to have any role in
genome replication, since mutations of either of these residues to
alanine or aspartic acid had no phenotype. In contrast, S229 was a
key residue since both the S229A and S229Dmutations abrogated
RNA replication. Consistent with this, a subgenomic replicon
with a triple mutation of S228/229/230 to either alanine or aspar-
tic acid was also replication defective. S232 resembled S225 in that
the S232A mutation reduced replication approximately 10-fold,
whereas S232D exhibited wild-type activity. These data point to
important roles for S229 and S232 in HCV genome replication; at
this stage, it is pertinent to note that these residues were identified
as phosphoacceptors in the tri- and tetraphosphorylated peptides
but in configurations that could not be unambiguously assigned.
Western blot analysis ofNS5A expression in cells harboring the
subgenomic replicons reflected the levels of replication (Fig. 4B);
however, this analysis led to an intriguing observation regarding
the mobility of the two phosphorylated forms. Whereas the mo-
bility of the hyperphosphorylated species did not vary, there were
differences in the mobilities of the basally phosphorylated species
between the various mutants. Specifically, although alanine sub-
stitutions did not change the mobility of the basally phosphory-
lated species compared to that of the wild type, aspartic acid sub-
stitutions resulted in a subtle retardation of its mobility. This
could also be seen to a lesser extent for mutation S225 and the
combination of S222/225 but interestingly not for S146 or T348
(Fig. 2), suggesting that this was not simply due to the substitution
of an acidic residue into the protein. To obtain a clearer picture of
this phenomenon, we analyzed all of the phosphomimetic mu-
tants capable of replication (therefore excluding the S229D mu-
tant) on a single Western blot (Fig. 5). For completeness, we also
included the S235D and S238Dmutants, which were also replica-
tion competent (Fig. 6). Although the overall levels of expression
varied, a clear trend emerged: as the position of the phosphomi-
metic mutation moved toward the C terminus of this serine clus-
ter, the mobility of the basally phosphorylated species was pro-
gressively retarded. One explanation for this result is that
phosphorylation of one residue completes the kinase recognition
motif for a neighboring residue to be phosphorylated and so on,
resulting in a sequential phosphorylation cascade.
Regulation of hyperphosphorylation by S146. As shown in
Fig. 2 and 3, the S146D mutation resulted in a reduction in the
level of hyperphosphorylation, suggesting that phosphorylation
of this residue in some way negatively regulated phosphorylation
FIG 3 Mutagenic analysis of phosphorylation in the context of JFH-1 virus.
The indicated mutations were engineered into mJFH-1 (29), and in vitro-
transcribed RNA was electroporated into Huh7 cells. Cells were cultured for
144 h, including a 1:5 passage at 72 hpe, total RNA was extracted from cells at
72 and 144 hpe, and HCV genomes were quantified by qRT-PCR using prim-
ers targeted to the 5= UTR (31) (n  3). , P  0.05, significant different from
the wild type. HCV genomes for the nonreplicating control, GND, were still
detectable,most likely due to the stability of the 5=UTR. (B) Supernatants were
assayed for released infectious virus titer by focus-forming assay at 72 and 144
hpe. ffu, focus-forming units. (C) Lysates were prepared from cells at 144 hpe
and probed for NS5A (9E10), Core, and GAPDH. “SSAA” refers to the S222/
225A double mutant; “SSDD” refers to the corresponding S222/225Dmutant.
FIG 4 Mutagenic analysis of putative phosphorylation sites within LCS I. The
indicated mutations were engineered into mSGR-Luc-JFH-1 (29), in vitro-
transcribed RNA was electroporated into Huh7 cells, and luciferase activity
measured at 4 and 72 hpe. A polymerase-inactive mutant, GND, was included
as a negative control. (A) Luciferase activity at 72 hpe is shown (n  3) nor-
malized to activity at 4 h. , P  0.05, significant difference from the wild type.
(B)Western blot analysis of cell lysates at 72 hpe probed with NS5A (9E10) or
GAPDHantibodies. “SSSAAA” refers to the S228/229/230A triplemutant, and
“SSSDDD” refers to the corresponding S228/229/230D mutant.
FIG 5 Phosphomimetic mutations in LCS I increase the apparent molecular
weight of the basally phosphorylated NS5A species. Lysates from electropo-
rated cells were prepared at 72 hpe and analyzed by Western blotting with
antibodies to NS5A (9E10) or GAPDH. Lysates were separated by 7.5% SDS-
PAGE at low voltage for an extended time (110 V, 120 min), allowing for
optimal resolution of basally and hyperphosphorylated forms. The NS5A
Western blot is shown at both low and high exposures.
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at other sites (possibly within the serine-rich LCS I). We reasoned
that if sequential phosphorylation with LCS I contributed to hy-
perphosphorylation, then the introduction of phosphomimetic
mutations might override this effect of S146D. To test this, we
generated a series of phosphomimetic mutations in LCS I in the
background of the S146D mutation within the SGR-luc-JFH-1
subgenomic replicon and evaluated replication by luciferase assay
and NS5A expression by Western blotting. In both assays, we
compared the mutant panel in either a wild-type or S146D back-
ground.
Figure 6 shows that for S225D, S228D, S230D, S232D, and
S238Dmutants, the addition of the S146Dmutation had no effect
on replication, since all of these subgenomic replicons were indis-
tinguishable from the wild type. As previously shown (Fig. 4A),
the S229D mutant was completely replication defective, and this
was not changed by the introduction of the S146Dmutation. Two
mutations, S222D and S235D, showed an altered phenotype,
whereby in the wild-type background these mutations had no ef-
fect on replication, but in combination with S146D, viruses car-
rying both exhibited impaired replicative capacity (approximately
1- or 2-log reductions, respectively). Western blot analysis of cell
lysates showed two distinct features. First, the introduction of
S146D alongside LCS I mutations (S228D, S230D, S232D, and
S238D) did not block their ability to increase the apparent molec-
ular weight of the basally phosphorylatedNS5A (Fig. 7A). Second,
the presence of any phosphomimeticmutationwithin LCS I (222–
238) did not block the ability of S146D to reduce hyperphos-
phorylation of NS5A, since in all cases where the double mutants
were capable of replication, the presence of S146D reduced the
abundance of hyperphosphorylation (Fig. 7B). These data show
that the phenotype of both S146 and LCS I phosphomimetic mu-
tations cannot elicit a dominant effect over the other.
S222 phosphorylation is a hallmark of the hyperphosphory-
lated NS5A species. It has been previously suggested that S222 is a
critical phosphoacceptor in the formation of the hyperphos-
phorylated NS5A species. However, the evidence for this is indi-
rect, and differential phosphorylation of S222 between the basally
and hyperphosphorylated species was not demonstrated. In order
to determine the phosphorylation status of S222 in the two species
ofNS5A,we raised a sheep polyclonal phospho-specific antiserum
using an appropriate phosphopeptide. Figure 8A presents a vali-
dation of this reagent and shows that the anti-pS222 antiserumdid
indeed react only with the hyperphosphorylated NS5A species. A
very faint band can be seen corresponding to basally phosphory-
latedNS5A; however, this ismost likely due toweak recognition of
the surrounding peptide sequence. Reassuringly, the serum
showed only very limited cross-reactivity with the S222A or
S222Dmutants; again the faint bands are likely due to recognition
of the surrounding sequence. This is the first biochemical evidence
that S222 phosphorylation is enriched in the hyperphosphory-
lated NS5A species, although we cannot rule out that it is also
FIG 6 Analysis of LCS I phosphomimetic mutations in the context of S146D.
The indicated mutations were engineered into mSGR-Luc-JFH-1 (29), in
vitro-transcribed RNA was electroporated into Huh7 cells, and luciferase ac-
tivity measured at 4 and 72 hpe. A polymerase-inactive mutant, GND, was
included as a negative control. (A) Luciferase activity at 72 hpe is shown (n 
3) normalized to activity at 4 h. For eachmutant, the results obtained in either
a wild-type (gray bars) or S146D mutant (black bars) background are shown
side by side. , P  0.05, significant difference from the wild type.
FIG 7 Effect of S146D on LCS I phosphorylation. Lysates from electroporated cells were prepared at 72 hpe and analyzed by Western blotting with antibodies
to NS5A (9E10) or GAPDH. Lysates were separated by 7.5% SDS-PAGE at low voltage for an extended time (110 V, 120 min),1 allowing for optimal resolution
of basally and hyperphosphorylated species. For each mutant, the results obtained in either a wild-type (-) or S146Dmutant () background are shown side by
side. (B) Quantification of the percentage of total NS5A that is hyperphosphorylated fromWestern blots. Western blots were imaged using a Li-Cor Odyssey Sa
infrared imaging system, enabling highly accurate quantification (n  3). For eachmutant, the results obtained in either a wild-type (gray bars) or S146Dmutant
(black bars) background are shown side by side. , P  0.01, significant difference from the wild type. n.d, no data due to low levels of expression.
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present at very low levels in the basally phosphorylated species.
Consistent with the loss of the hyperphosphorylated species for
the S146D mutant (see Fig. 2B), Western blot analysis using anti-
pS222 antiserum revealed that pS222 reactivity wasmuch reduced
for this mutant (Fig. 8B). These data provides further confirma-
tion of the role of S146 in regulating phosphorylation within LCS
I. Further Western blot analysis also demonstrated that the phos-
phomimetic S222D to S238D mutants were also able to increase
the reactivity of the basally phosphorylated species toward the
pS222 antibody (Fig. 8C).
DISCUSSION
Wepresent in this article a comprehensive analysis of NS5A phos-
phorylation in a physiologically relevant context, i.e., from Huh7
cells harboring a JFH-1-derived subgenomic replicon. Our study,
together with a recent publication (25), represents the only bio-
chemical analyses of NS5A phosphorylation expressed in human
cells in the context of the other nonstructural proteins and an
active RNA replication complex. Both studies identified S222
within LCS I as a major site of phosphorylation (25). However,
whereas Lemay et al. only showed S222 to be a phosphoacceptor,
our data identified a large number of other sites of phosphoryla-
tion, not only in LCS I but in domains I and III and LCS II. The
difference between the two studies is likely due simply to the
amount of starting material—LeMay et al. used 7.5  107 cells,
while our study used approximately 100-foldmore, thereby allow-
ing the identification of phosphopeptides that are detected with a
lower efficiency byMS (peptides that are large and/or highly phos-
phorylated), as well as those that are less abundant. To overcome
the absence of trypsin cleavage sites in the C-terminal 121 residues
of NS5A, we also digested the purified protein with GluC. Despite
this, we were still unable to detect the putative phosphoacceptor
S457 in domain III (12, 29), which was likely a result of peptides
containing that modification being at low abundance or contain-
ingmultiple phosphorylations. Neither study was able to discrim-
inate between phosphoacceptors present on the basally and/or
hyperphosphorylated NS5A species, due to the loss of resolution
when separating large amounts of protein by SDS-PAGE. It is
important to note that during the propagation of subgenomic
replicon-harboring cells for NS5A purification, we endeavored to
use cells at a low passage number. The reason for this is that we
have routinely observed a loss of the hyperphosphorylated species
following long-termpassage of replicon cell lines (see Fig. S5 in the
supplemental material for an example). Sequence analysis of rep-
licons following long-term passage did not reveal any mutations
in NS5A (data not shown), so this is most likely caused by changes
in cellular gene expression, although we cannot rule out muta-
tions in other nonstructural proteins.
Threonine 348: an “orphan” phosphoacceptor with no phe-
notype. Our analysis identified T348 within LCS II as a phospho-
acceptor. Although T348 is not conserved in other genotypes of
HCV (in genotype 1, this residue is a valine or isoleucine), in
genotype 1a (strain H), a serine just before the PxxPxR motif was
identified as a phosphoacceptor, albeit in the context of expression
of a GST-NS5A fusion in BHK21 cells (17). Thus, there is prece-
dent for the existence of a phosphorylatable residue in this region
of the protein. Neither a phosphoablatant nor phosphomimetic
mutation at this site had any phenotype in replication and/or virus
assembly, but it was intriguing that this residue was located in the
middle of a well-characterized class II polyprolinemotif (PxxPxR)
that binds to a range of SH3 domains (33, 34).We considered that
phosphorylation at T348 might influence the binding of NS5A to
SH3 domains; however, as shown in Fig. S6 in the supplemental
material, this was not the case. Both the T348A and T348D mu-
tants bound aswell as thewild type to a range of GST-SH3 domain
fusion proteins in an in vitro GST pulldown assay using lysates
from subgenomic replicon-harboring Huh7 cells. In contrast, the
PA2 mutant (in which the prolines were substituted for alanines)
failed to bind to GST-SH3 fusions. Thus, the potential role of this
phosphorylation event remains elusive.
LCS I is the predominant location for phosphorylation of
NS5A.Themajority of phosphoacceptor residues identified in this
study were in LCS I, between S222 and S238. Remarkably, this
serine-rich cluster is absolutely conserved across all genotypes of
HCV, implying an essential role in the virus life cycle. A 19-residue
tryptic peptide covering this region contained 8 serines, and our
mass spectrometric data provided evidence for the existence of
unique phosphorylated species containing between 1 and 7 phos-
phorylated serines. Our data do not preclude the presence of an
8th phosphorylated serine. In agreement with others (18, 25), we
believe that the most abundant phosphorylation event is on S222.
LeMay et al. also provided evidence for phosphorylation of S222
being present in the hyperphosphorylated NS5A form, as shown
by a 36% reduction in hyperphosphorylation in the context of the
S222A mutant. By generating an antiserum specific to phospho-
S222, we here provide the first definitive evidence that phosphor-
ylation of S222 is indeed a hallmark of hyperphosphorylated
NS5A, since the antiserum showed very little reactivity to the ba-
sally phosphorylated NS5A species or the hyperphosphorylated
S222A or S222D mutants (Fig. 8). However, despite the fact that
S222 phosphorylation was detected predominantly in the hyper-
phosphorylated species, in our hands mutation at this residue did
not affect the ratio of hyper- to basally phosphorylated NS5A
FIG 8 Phosphorylated S222 is predominately in the hyperphosphorylated
species. A phospho-specific antibody was raised in sheep against pS222 using
an appropriate 13-mer peptide and purified by IgG enrichment. (A) Specificity
of the pS222 antibody. Lysates from Huh7 cells electroporated with the indi-
cated subgenomic replicons were analyzed by SDS-PAGE/Western blotting
and probed with either anti-pS222 (left panel), or anti-NS5A (right panel)
sheep polyclonal antisera. (B) Indicated lysates were probed with the anti-
pS222 antiserum. (C) Lysates were probed with anti-NS5A (upper panel) or
anti-pS222 (lower panel).
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(Fig. 7). This suggests that phosphorylation of S222 alone is nei-
ther the sole component of nor sufficient to produce the hyper-
phosphorylated species. Additionally, mutation of S222 to either
A or D had no effect on RNA replication, the only phenotype
being a modest yet significant reduction in the titer of released
virus for S222D.
To complement the biochemical analysis of phosphorylation,
we conducted an extensivemutagenesis of the identified phospho-
acceptor residues. Many of these mutants had no phenotype, but
this analysis pointed to a critical role for S229: both phosphoabla-
tant and phosphomimetic mutations at this site abrogated repli-
cation of the subgenomic replicon, in agreement with the recent
data of Fridell and coworkers (24). The observation that both
types of mutations at this residue were lethal might suggest that
although this serine residue is phosphorylated, it plays an addi-
tional role that is not dependent on phosphorylation. In contrast,
and again in agreement with the work of Fridell (24), the S225A
mutant had a partial defect in replication; this was restored by the
S225Dmutation, consistentwith a role for phosphorylation at this
residue.
None of the mutations within LCS I stimulated RNA replica-
tion, which is in contrast to the situation in the genotype 1b
(Con1) subgenomic replicon (22). In fact, it appears that the ge-
notype 2amutations exhibit the phenotype opposite to that of the
corresponding mutations in genotype 1b, despite the absolute
conservation of the sequence (see Table S1 in the supplemental
material). For example, mutations of S229 in genotype 1b signif-
icantly enhance replication, yet the same mutations are lethal in
genotype 2a. These differences are hard to interpret but presum-
ably are indicative of fundamental genotype-specific differences in
the interactions between NS5A and other viral (or cellular) pro-
teins during the process of virus genome replication.
Evidence for sequential phosphorylation across LCS I. Dur-
ing our analysis, we observed that for the phosphomimetic (S ¡
D) mutations within LCS I, the mobility of the basally phosphor-
ylated species appeared to vary betweenmutants, whereas themo-
bility of the hyperphosphorylated species did not change, with the
exception of the S235Dmutant, which exhibited a slight, but con-
sistent increase inmobility. A clear trend emerged whereby, as the
position of the phosphomimetic mutation was shifted further to-
ward the C terminus of LCS I, there was a concomitant decrease in
themobility (increase in apparentmolecular weight) of the basally
phosphorylated species (Fig. 4). One interpretation of these data is
that there is a sequential and ordered cascade of phosphorylation
events across this region. In this scenario, a phosphorylated amino
acid is an essential component of the recognition motif for a ki-
nase that phosphorylates a proximal residue, either N- or C-ter-
minal to the preexisting phosphorylation site. This phosphoryla-
tion event then serves to “prime” the phosphorylation of the next
residue in a similar manner. In this scenario, phosphorylation at
S238 would enable phosphorylation at S235 and so on. There are
many examples of sequential phosphorylation cascades in cellular
proteins: for example, GRASP65 (35) and PTEN (36). In the latter
case, one cascade is not linear; for example, phosphorylation in
PTEN proceeds from S385 ¡ S380 ¡ T383 ¡ T382. Our data
cannot rule out such a process in NS5A, and the identification of
the phosphorylating kinases coupled with a sophisticated tempo-
ral NMR analysis would be required to address this question in
more detail, as in the case of PTEN. Interestingly, another protein
exhibiting sequential phosphorylation is	-catenin, which also in-
teracts with NS5A (37). In 	-catenin, S45 is phosphorylated by
CKI, which primes it for subsequent phosphorylation at S41, S37,
and S33 by GSK-3 (38). A similar scenario could be envisioned for
NS5A, and intriguingly, S222 and S225 are predicted to constitute
GSK3 phosphorylation sites. By mimicking phosphorylation, the
S238D mutation would force sequential phosphorylation across
the entire LCS I, whereas S ¡ Dmutations located N-terminal to
S238 would only drive a subset of the possible phosphorylation
events. This hypothesis is consistent with the notion that addition
of multiple phosphates to LCS I would therefore contribute to the
hyperphosphorylation phenotype. The fact that, in the case of
wild-type NS5A, no intermediates between the basally and hyper-
phosphorylated forms are seen suggests that once the phosphory-
lation cascade begins, it proceeds to completion. Additionally, the
presence of both forms implies that the phosphorylation cascade
is an all-or-nothing series of events. NS5A species of intermediate
apparent molecular weight can only form when the cascade is
perturbed, for example, by introduction of a phosphomimetic
mutant which overcomes any regulation of the phosphorylation
cascade. However, even in the S238D mutant, where we see the
largest increase in apparent molecular weight, the basally phos-
phorylated and hyperphosphorylated species can still be distin-
guished, so clearly additional phosphorylation events are neces-
sary to generate the hyperphosphorylated species. One candidate
is the other phosphoacceptor identified in this study, S146.
S146 regulates hyperphosphorylation. S146 is located within
domain I and has not previously been identified as a phosphoac-
ceptor. Mutation of this site had no effect on either genome rep-
lication or virus assembly; however, it was noteworthy that the
S146D mutant exhibited a significant decrease in the abundance
of hyperphosphorylated NS5A, decreasing from 42% (
0.6 stan-
dard error of the mean [SEM]) of total NS5A for the wild type to
17% (
1.0 SEM) for the S146D mutant. However, this was not
accompanied by a concomitant increase in the abundance of the
basally phosphorylated species, suggesting that in the absence of
S222 phosphorylation, partially hyperphosphorylated NS5A
might be subject to rapid degradation.
The S146D mutant also exhibited a loss in reactivity to the
phospho-S222 antiserum, consistent with the fact that S222 phos-
phorylation is a hallmark of the hyperphosphorylated species and
is downregulated by the S146Dmutation. Given that phosphomi-
metic mutations in LCS I appeared to at least partially drive the
conversion of the basally phosphorylated species into the hyper-
phosphorylated species, we investigated whether these mutations
could override the inhibitory effect of S146D on hyperphosphory-
lation. However, this was not the case, and furthermore, the addi-
tion of S146D was not able to block the increase in apparent mo-
lecular weight of the basally phosphorylated species that resulted
from LCS I phosphomimetic mutations. We therefore propose
that a number of factors contribute to the hyperphosphorylation
of NS5A. First, sequential phosphorylation across LCS I is re-
quired, and second, hyperphosphorylation is negatively regulated
by phosphorylation at S146 (Fig. 9A). We further propose, based
on the observation that the S146D/S238Dmutant still exhibits two
species of distinct mobility, that additional (as yet undefined)
phosphorylation events are required to produce the hyperphos-
phorylated species of NS5A.
Our data do not support the previously proposed hypothesis
that hyperphosphorylation inhibits genome replication.We iden-
tify mutations that significantly reduce hyperphosphorylation yet
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have no effect on either genome replication or virus assembly and
release (e.g., S146D and S225D). A caveat to this conclusion is that
NS5A expression from replication-defective mutants (e.g., the
S222/225A and S229A/D mutants) is below the Western blot de-
tection threshold. Thus, it is formally possible that these mutants
have high levels of hyperphosphorylation; however, at least for the
S225A mutant, this appears not to be the case, since this mutant
exhibits both low levels of replication and hyperphosphorylation.
It may be that the high replicative capacity of JFH-1 overcomes
any dependence on hyperphosphorylation which is seen in geno-
type 1b replicons (11, 22).
Interestingly, a serine at residue 146 is present only in genotype
1a and 2a isolates of HCV; in the majority of other isolates across
all genotypes and subtypes (including 1b and 2b), this residue is an
alanine, although the surrounding sequence is highly conserved. It
is therefore possible that the presence of a phosphorylatable resi-
due at this position might contribute to the enhanced replicative
capacity of JFH-1 by allowing for an additional level of control of
hyperphosphorylation. Further, albeit circumstantial, evidence
supporting this hypothesis comes from an examination of the two
published structures of domain I. As shown in Fig. 9B, there are
two differing dimeric conformations of NS5A domain I, the
“closed” conformation (3FQM) (5) and the “open” conformation
(1ZH1) (6). Both structures utilized the genotype 1b Con1 se-
quence, in which an alanine is present at position 146. In the
closed conformation, A146 is located close to the dimer interface,
whereas in the open conformation, it is on the opposite face of
each monomer. In the closed conformation, a proximal residue,
E148 (conserved in both JFH-1 and Con1), forms an intramolec-
ular contact via a hydrogen bond with R112 on the other mono-
mer. While it is not possible to predict the effects of S146 phos-
phorylation on dimer formation, two scenarios are possible. First,
the negative charge imparted by S146 phosphorylation could par-
ticipate in an electrostatic interaction with R112 on the other
monomer (Fig. 9B), potentially stabilizing the dimer interface.
Alternatively, S146 phosphorylation could disrupt the interaction
between R112 and E148, thereby promoting a switch from the
closed to the open conformation. Whether phosphorylation of
S146 might affect the NS5A conformation at the point of
dimerization or be involved in switching between conformations
of dimeric NS5A remains to be determined. To further support
the potential involvement of S146 phosphorylation in regulating
dimerization, we modeled the structural consequences of a glu-
tamic acid substitution at position A146 using the Robetta full-
chain protein structure prediction server. As shown in Fig. S7 in
the supplemental material, this analysis predicted that phosphor-
ylation at this residue could indeed project further into the dimer
interface, consistent with a role for S146 phosphorylation in reg-
ulating dimerization; however, such analysis does not allow us to
predict whether phosphorylation of S146 would favor the closed
or open conformation.
In summary, our data provide novel insights into the complex-
ity and regulation of NS5A phosphorylation. They provide a
framework for future studies, which will seek to identify the ki-
nases involved in these events and dissect the roles of the different
phosphorylated forms of NS5A in the virus life cycle. Further-
more, NS5A phosphorylation is likely to be a dynamic process,
therefore also requiring the action of protein phosphatases, such
as PP2A, which has been shown to be upregulated by HCV infec-
tion (39) and to interact with NS5A (40). We hope that these
studies will not only lead to a deeper understanding ofNS5A func-
tion but provide opportunities for the development of new ther-
apeutic options for HCV treatment.
FIG 9 Summary and potential role of NS5A phosphorylation. (A) Schematic of NS5A showing the location and relationship of phosphorylation events
identified.Domain I is denoted by the structure of theCon1monomer (6); sequences of LCS I and LCS II are shown; domains II and III are denoted by gray boxes.
Highlighted in red are those residues identified as phosphorylation sites. Note that residues S228 and S238 were not observed directly by mass spectrometry, but
the presence of a heptaphosphorylated phosphopeptidewith only 8 possible phosphorylation sites strongly indicates their presence. (B) The twodiffering dimeric
conformations of NS5A domain I are shown, “closed” (3FQM) (5) and “open” (1ZH1) (6), green/purple and purple/yellow, respectively. The structural studies
utilized a Con1 sequence where an alanine is present at position 146. Residue E148b (conserved in JFH-1 and Con1) forms an intramolecular bond with R112a
on the opposite monomer, blue and orange, respectively (5). It is likely that phosphorylation at 146 would exert an effect on this key dimer interaction of the
“closed” conformation.
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